|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 28, 2017 ) ReportsWeb.com has announced the addition of the “Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016” The report outlines the evolution of enterprise content management, and identifies and assesses the best performing vendors in the market.
Summary
Latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease - Pipeline Review, H2 2016, provides an overview of the Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline landscape.
Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 9, 4, 1, 6, 2 and 1 respectively.
Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/anemia-in-chronic-kidney-disease-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001530742/sample
Few Points from Table of Content:
List of Tables 7
List of Figures 8
Introduction 9
Report Coverage 9
Anemia in Chronic Kidney Disease (Renal Anemia) Overview 10
Therapeutics Development 11
Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) - Overview 11
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics under Development by Companies 12
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Anemia in Chronic Kidney Disease (Renal Anemia) - Products under Development by Companies 19
Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development 22
3SBio Inc 22
Acceleron Pharma Inc 23
Aevi Genomic Medicine Inc 24
Akebia Therapeutics Inc 25
Amgen Inc 26
Bayer AG 27
Biocad 28
CCM Duopharma Biotech Bhd 29
Chong Kun Dang Pharmaceutical Corp 30
CJ HealthCare Corp 31
Daiichi Sankyo Company Ltd 32
Dong-A Socio Holdings Co Ltd 33
Dr. Reddy's Laboratories Ltd 34
FibroGen Inc 35
GlaxoSmithKline Plc 36
Intas Pharmaceuticals Ltd 37
Japan Tobacco Inc 38
JCR Pharmaceuticals Co Ltd 39
Jiangsu Hansoh Pharmaceutical Co Ltd 40
LG Life Science LTD 41
Myungmoon pharmaceutical Co Ltd 42
Panacea Biotec Ltd 43
Pfizer Inc 44
PharmaEssentia Corp 45
PhytoHealth Corp 46
Pieris Pharmaceuticals Inc 47
Reliance Life Sciences Pvt Ltd 48
Sandoz International GmbH 49
Zydus Cadila Healthcare Ltd 50
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
daprodustat - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
darbepoetin alfa - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
darbepoetin alfa - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
darbepoetin alfa - Drug Profile 67
Product Description 67
Mechanism Of Action 67
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001530742/buy/2000
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
